Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is Moderna Still a Compelling Growth Play?

TheMotleyFool

0 0

Is Moderna Still a Compelling Growth Play?Photo, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

Moderna (NASDAQ: MRNA) has had a banner year in 2020. Thanks to the biotech's COVID-19 vaccine candidate mRNA-1273, the company's shares have gapped up by an eye-catching 400% this year.

The biotech's red-hot growth streak, though, may be nearing an end. BMO Capital analyst George Farmer, for instance, said earlier this week that he believes mRNA-1273's commercial potential is already priced into the company's valuation at this point.

Image source: Getty Images.

Source Fool.com

Like: 0

MRNA

Teilen